Jonas Salk, who
passed away on 23 June 1995 in La Jolla, California, was an American
physician and medical researcher who developed the first safe and effective
vaccine for polio.
Salk
received an M.D. in 1939 from New York University College of Medicine, where he
worked with Thomas Francis Jr., who was conducting killed-virus immunology
studies. Salk joined Francis in 1942 at the University of Michigan School
of Public Health and became part of a group that was working to develop
an immunization against influenza.
In 1947 Salk became associate professor of bacteriology
and head of the Virus Research Laboratory at the University of Pittsburgh School
of Medicine. At Pittsburgh he began research on polio, an acute
viral infectious disease of the nervous system that usually begins with general
symptoms such as fever and headache and is sometimes followed by a more
serious and permanent paralysis of muscles in one or more limbs, the throat, or
the chest. In the mid-20th century hundreds of thousands of children were
struck by the disease every year. Working with scientists from other
universities in a program to classify the various strains of poliovirus, Salk corroborated
other studies in identifying three separate strains. He then demonstrated that
killed virus of each of the three, although incapable of producing the disease,
could induce antibody formation in monkeys.
In 1952 he
conducted field tests of his killed-virus vaccine, first on children who
had recovered from polio and then on subjects who had not had the disease; both
tests were successful in that the children’s antibody levels rose significantly
and no subjects contracted polio from the vaccine. His findings were published
the following year. In 1954 Francis conducted a mass field trial, and the
vaccine, injected by needle, was found to safely reduce the incidence of polio.
On 12 April 1955, the vaccine was released for use in the United States. In
the following years the incidence of polio in the United States fell from 18
cases per 100,000 people to less than 2 per 100,000. In the 1960s a second type
of polio vaccine, known as oral poliovirus vaccine (OPV) or Sabin vaccine
- named for its inventor, American physician and microbiologist Albert Sabin — was
developed. OPV contains live attenuated (weakened) virus and is given
orally.
Salk served
successively as professor of bacteriology, preventive medicine, and
experimental medicine at Pittsburgh, and in 1963 he became fellow and
director of the Institute for Biological Studies in San Diego, California, later
called the Salk Institute. Among his many honours was the Presidential Medal
of Freedom, awarded in 1977.
No comments:
Post a Comment